{"entity":{"id":"nct03915184","kind":"trial","name":"Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2)","aka":[],"tldr":"A phase 1/2 trial of Zevorcabtagene autoleucel in multiple myeloma, run by CARsgen Therapeutics Co., Ltd., active and no longer recruiting.","summary":"Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2) is a phase 1/2 interventional study registered as NCT03915184 by CARsgen Therapeutics Co., Ltd., with 105 participants planned, started 2019-09-25 and due to reach its primary completion in 2024-12-31. Interventions recorded: zevor-cel. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT03915184","url":"https://clinicaltrials.gov/study/NCT03915184"}],"tags":["ctgov-ingest"],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":[],"targets":[],"drugs":["zevorcabtagene-autoleucel"],"companies":["carsgen"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT03915184","phase":"1/2","setting":"Open Label, Multi-center, Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of Autologous CAR BCMA T Cells (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2)","sponsor":"CARsgen Therapeutics Co., Ltd.","enrolled":105,"outcomes":[]},"route":"/trials/nct03915184/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"drug":[{"id":"zevorcabtagene-autoleucel","kind":"drug","name":"Zevorcabtagene autoleucel","route":"/drugs/zevorcabtagene-autoleucel/"}],"company":[{"id":"carsgen","kind":"company","name":"CARsgen Therapeutics","route":"/companies/carsgen/"}]}}